Due to typographical error, the company inadvertently mentioned wrong number in few lines of Financial results as mentioned in Annexure I. Please note that there is no change in broader ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Eiko Lifesciences has submitted a revised board meeting outcome to correct typographical errors in its audited standalone and consolidated financial results for Q4 and FY ended 31 March 2025. The company clarifies that there is no change in the broader heads of financials; only internal numbers have been re-arranged. For FY25 on a standalone basis, revenue from operations rose to INR 3,249.18 lakhs (vs INR 2,792.93 lakhs in FY24), while profit after tax more than doubled to INR 174.08 lakhs (vs INR 75.15 lakhs). Consolidated FY25 revenue was INR 3,766.40 lakhs with PAT of INR 231.86 lakhs. The statutory auditor (PSV Jain & Associates) issued an unmodified opinion. The board also appointed M/s Shravan Gupta & Associates as Secretarial Auditor for 5 years and M/s NP Rajput & Co as Internal Auditor for FY26.
This is primarily a correction filing rather than a fundamental change, so material impact on shareholder value is limited. The strong standalone earnings growth and clean audit opinion are positives, while the FY25 PAT includes an exceptional item (interest from delayed rights call money) that is non-recurring in nature.